PIER MARIA FORNASARI

PIER MARIA FORNASARI
2019-09-10

Exosomes from Adipose-Derived Stem Cells (ADSCs) Overexpressing miR-21 Promote Vascularization of Endothelial Cells

miR-21 has been indicated to be an important regulator of angiogenesis, involving in regulating the proliferation and migration of vascular cells, like endothelial cells. Direct evidences have shown that downregulation of miR-21 expression signifcantly reduces the proliferation and migration of HUVECs, and conversely, miR-21 overexpression signifcantly enhances HUVECs proliferation and migration, indicating the importance of

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-09-10

Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies

Pluripotent stem cells (PSCs) represent an attractive cell source for treating muscular dystrophies (MDs) since they easily allow for the generation of large numbers of highly regenerative myogenic progenitors. Using reprogramming technology, patient-specific PSCs have been derived for several types of MDs, and genome editing has allowed correction of mutations, opening the opportunity for their

No Comments InCELL THERAPY

PIER MARIA FORNASARI
2019-09-10

T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma

The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. ADP-A2M4 (Adaptimmune) is an autologous, genetically modified SPEAR T-cell therapy that targets the MAGE-A4 antigen on the surface of cancer cells. Certain soft tissue sarcomas express MAGE-A4 at high levels and

No Comments InCANCER

PIER MARIA FORNASARI
2019-09-10

The diet-microbiome connection in inflammatory bowel disease

Dogs with a Crohn’s-like disease fed a special diet were found to have characteristic changes in their gut microbiomes, paralleling changes seen in children with Crohn’s. uch remains mysterious about the factors influencing human inflammatory bowel disease (IBD), but one aspect that has emerged as a key contributor is the gut microbiome, the collection of

No Comments InMICROBIOME

PIER MARIA FORNASARI
2019-09-10

Success of gene therapy for a form of inherited blindness depends on timing

An FDA-approved gene therapy for Leber congenital amaurosis, an inherited vision disorder with a childhood onset and progressive nature, has improved patients’ sight. But new research underscores the importance of further investigation to halt the progression of the disorder. Nearly two decades ago, a gene therapy restored vision to Lancelot, a Briard dog who was

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-09-10

Two therapies cure rare genetic disease in mice

In pair of studies, UCLA researchers describe new ways to treat a metabolic liver disorder Source UCLA Newsroom Most babies who are born with arginase deficiency — a rare genetic disease that leads to the accumulation of the amino acid arginine in the blood — don’t have symptoms at first. By the time they’re toddlers,

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2019-09-09

Scientists triple storage time of human donor livers

NIH-funded research project develops new method to preserve human livers for transplantation. Source NIH Scientists have greatly extended the amount of time human livers can be stored for transplantation by modifying a previous protocol to extend the viability of rat livers. Previously, human livers were only viable for an average of nine hours, but the

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-09-09

Reconsidering Osteoconduction in the Era of Additive Manufacturing

Source https://www.liebertpub.com/doi/full/10.1089/ten.teb.2019.0047#utm_source=FastTrack&utm_medium=email&utm_campaign=teb Bone regeneration procedures in clinics and bone tissue engineering stand on three pillars: osteoconduction, osteoinduction, and stem cells. In the last two decades, the focus in this field has been on osteoinduction, which is realized by the use of bone morphogenetic proteins and the application of mesenchymal stem cells to treat bone defects.

No Comments InBIOPRINTING

PIER MARIA FORNASARI
2019-09-09

Stem cell company receives €3 million backing for mass therapy production

Stem cell company TreeFrog Therapeutics has received close to €3 million in non-dilutive funding from French and European programs. The company received €450,000 from the French government as part of Phase 2 of the i-Nov Innovation Challenge, as well as €2.4 million from the European Commission as part of Phase 2 of the SME Instrument.

No Comments InREGENERATIVE MEDICINE

PIER MARIA FORNASARI
2019-09-09

Northwestern University Stem Cell Therapy Clinic Closes Abruptly

A Chicago-based center that has long operated a clinical trial program for stem cell therapies, has stopped recruiting further patients as its chief, Richard Burt, leaves for a research sabbatical. Source The Scientist A pioneering stem cell clinical trial program in the US is closing up shop, a surprise move for what had appeared to

No Comments InCELL THERAPY

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

All posts by PIER MARIA FORNASARI

Exosomes from Adipose-Derived Stem Cells (ADSCs) Overexpressing miR-21 Promote Vascularization of Endothelial Cells

Pluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies

T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma

The diet-microbiome connection in inflammatory bowel disease

Success of gene therapy for a form of inherited blindness depends on timing

Two therapies cure rare genetic disease in mice

Scientists triple storage time of human donor livers

Reconsidering Osteoconduction in the Era of Additive Manufacturing

Stem cell company receives €3 million backing for mass therapy production

Northwestern University Stem Cell Therapy Clinic Closes Abruptly